Position paper on imatinib mesylate in chronic myeloid leukaemia.
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D001549:Benzamides; D017277:Drug Approval; D016527:Drug Costs; D005544:Forecasting; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000191:economics; D010879:Piperazines / Q000191:economics / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D011743:Pyrimidines / Q000191:economics / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D017211:Treatment Failure
D000970:Antineoplastic Agents; D001549:Benzamides; D016898:Interferon-alpha; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate